Auctus Advisors’s Perspective Therapeutics CATX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$103K Buy
37,359
+17,015
+84% +$51.6K 0.08% 30
2026
Q2
$69.4K Buy
20,344
+4,796
+31% +$18.1K 0.06% 34
2026
Q1
$64.8K Sell
15,548
-16,125
-51% -$68.1K 0.06% 29
2025
Q4
$87.1K Buy
+31,673
New +$90.4K 0.08% 26

Other funds holding CATX

Auctus Advisors's CATX Position: Q3 2026 in Review

Auctus Advisors increased its Perspective Therapeutics (CATX) stake by 84% in Q3 2026, buying an estimated $51.6K and bringing the position to 37,359 shares worth $103K. The position accounts for 0.08% of the portfolio, ranked #30.

Auctus Advisors first reported a position in CATX in Q4 2025 and has held it in 4 quarters since. 120 funds tracked by Wall St. Rank hold CATX as of Q3 2026.

  • Auctus Advisors held 37,359 shares of Perspective Therapeutics worth $103K as of Q3 2026.
  • Auctus Advisors bought 17,015 Perspective Therapeutics shares in Q3 2026, an estimated $51.6K.
  • Perspective Therapeutics made up 0.08% of Auctus Advisors's portfolio in Q3 2026, its #30 holding.
  • Auctus Advisors first reported a position in Perspective Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • 120 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q3 2026.

Based on Auctus Advisors's 13F filing for Q3 2026, filed 23 Oct 2026.